$AVDL News
Last published 2mo ago
- 2mo agoAVDLGOOGLNew Chrome-based Avid Media Composer video editing and conversational media search built with Google Cloud's Gemini Enterprise help creative teams collaborate securely from anywhereGoogle Cloud Press Corner
- 9mo agoALKSAVDLAlkermes plc Completes Acquisition of Avadel Pharmaceuticals plc, Accelerating Entry Into Sleep Medicine MarketBusiness Wire— Augments Alkermes' Revenue Growth Profile and Diversifies Commercial Portfolio with New High Potential Growth Product, LUMRYZ® (Sodium Oxybate) for Extended-Release Oral Suspension — — Expected to be Accretive
- 9mo agoAVDLAvadel Pharmaceuticals Announces Outcome of the Court Sanction HearingGlobeNewswireNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. DUBLIN, Feb. 10,
- 10mo agoAVDLAvadel Pharmaceuticals Announces that Avadel Shareholders Approve the Proposed Acquisition by AlkermesGlobeNewswireNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. DUBLIN, Jan. 12,
- 10mo agoAVDLAvadel Pharmaceuticals Announces Completion of Enrollment in Phase 3 REVITALYZ™ Trial in Idiopathic HypersomniaGlobeNewswire- Data expected in Q2 2026 - DUBLIN, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced the
- 11mo agoALKSAVDLAnnouncement relating to despatch of Rule 15 proposalGlobeNewswireNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS IS AN
- 11mo agoAVDLAnnouncement relating to despatch of Definitive Proxy Statement and details of Scheme Meeting and Extraordinary General MeetingGlobeNewswireNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS IS AN
- 11mo agoAVDLAnnouncement relating to convening of Scheme Meeting and Extraordinary General MeetingGlobeNewswireNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS IS AN
- 11mo agoALKSAVDLAlkermes plc Announces Increased Offer to Acquire Avadel Pharmaceuticals plcPR NewswireAlkermes plc (Nasdaq: ALKS) ("Alkermes") and Avadel Pharmaceuticals plc (Nasdaq: AVDL) ("Avadel") today announced that the companies have reached...
- 11mo agoALKSAVDLAvadel Board of Directors Declares Lundbeck Proposal a "Company Superior Proposal"GlobeNewswireTHIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION
- 12mo agoALKSAVDLAvadel Receives Unsolicited Proposal from LundbeckGlobeNewswireTHIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION
- 1y agoAVDLFORM 8.1(a) & (b) - Avadel Pharmaceuticals plcGlobeNewswireU.K. DISCLOSURE, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Ap9 FORM 8.1(a) & (b)(Opening Position Disclosure) IRISH TAKEOVER PANEL OPENING POSITION DISCLOSURE UNDER RULE 8.1(a) AND (b) OF THE IRISH TAKEOVER PANEL ACT,
- 1y agoAVDLAvadel Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswire– Generated LUMRYZ™ net product revenue of $77.5 million, a 55% increase compared to third quarter 2024 – – Approximately 3,400 patients on LUMRYZ as of September 30, 2025, a 48% increase compared to September
- 1y agoALKSAVDLAlkermes plc Announces Agreement to Acquire Avadel Pharmaceuticals plcPR NewswireAlkermes plc (Nasdaq: ALKS) ("Alkermes") and Avadel Pharmaceuticals plc (Nasdaq: AVDL) ("Avadel") today announced that the companies have entered...
- 1y agoAVDLAvadel Pharmaceuticals and Jazz Pharmaceuticals Reach Global SettlementGlobeNewswireDUBLIN, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced the global settlement of all
- 1y agoAVDLAvadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireDUBLIN, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel's Board of
- 1y agoAVDLAvadel Pharmaceuticals Celebrates Five Years of Driving Growth in Sleep Research FundingGlobeNewswireA Media Snippet accompanying this announcement is available by clicking on this link. DUBLIN, Sept. 16, 2025 (GLOBE NEWSWIRE) -- The American Academy of Sleep Medicine Foundation (AASM Foundation) and Avadel
- 1y agoAVDLAvadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireDUBLIN, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel's Board of
- 1y agoAVDLAvadel Pharmaceuticals Plc (AVDL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)Earnings Call Transcripts
- 1y agoAVDLAvadel Pharmaceuticals to Present New Data on LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension at World Sleep 2025GlobeNewswire– 17 abstracts accepted, including one oral presentation – – Data from the REFRESH real-world study highlight efficacy of once-nightly sodium oxybate when switching from twice-nightly oxybates – – REFRESH study
- 1y agoAVDLAvadel Pharmaceuticals Strengthens Sleep Medicine Portfolio with Exclusive License of Valiloxybate from XWPharma LtdGlobeNewswire– Expands Avadel's pipeline with salt-free, artificial sweetener-free, once-at-bedtime oxybate for treatment of narcolepsy and idiopathic hypersomnia – – Initial pharmacokinetic (PK) and comparative bioavailability
- 1y agoAVDLAvadel Pharmaceuticals to Present at Upcoming Investor ConferencesGlobeNewswireDUBLIN, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will
- 1y agoAVDLAvadel Pharmaceuticals plc (AVDL) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoAVDLAvadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireDUBLIN, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel's Board of
- 1y agoAVDLAvadel Pharmaceuticals Reports Second Quarter 2025 Financial Results and Raises 2025 Revenue GuidanceGlobeNewswire-- Generated LUMRYZ™ net revenue of $68.1 million, a 64% increase compared to second quarter 2024, net income of $9.7 million and earnings per share of $0.10 -- -- 3,100 patients on LUMRYZ as of June 30, 2025, a
- 1y agoAVDLAvadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter 2025 Financial Results on August 7GlobeNewswireDUBLIN, Ireland, July 31, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a
- 1y agoAVDLAvadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireDUBLIN, July 21, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel's Board of
- 1y agoAVDLASL Strategic Value Fund Issues Open Letter to Avadel ShareholdersBusiness WireUrges Shareholders to Vote AGAINST All Director Nominees Amid Governance Failures and Calls for Independent Oversight of Annual Meeting Vote ASL Strategic Value Fund, LP (together with its affiliates, "ASL Strategic
- 1y agoAVDLASL Strategic Value Fund Issues Open Letter to Avadel ShareholdersBusiness WireCalls for all Avadel Shareholders to vote AGAINST all Director Nominees at the upcoming Annual Meeting ASL Strategic Value Fund, LP (together with its affiliates, "ASL Strategic Value Fund" or "we"), a significant
- 1y agoAVDLAvadel Pharmaceuticals Announces Unanimous Appeals Court Decision Upholding FDA Approval of LUMRYZ in Narcolepsy in Administrative Procedure Act LitigationGlobeNewswireDUBLIN, June 30, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced that, on Friday, June 27, 2025, the U.S.
- 1y agoAVDLAvadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireDUBLIN, June 16, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel's Board of
- 1y agoAVDLAvadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic HypersomniaGlobeNewswireDUBLIN, June 05, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that LUMRYZTM has been granted
- 1y agoAVDLAvadel Pharmaceuticals to Present New Data on LUMRYZ™ (sodium oxybate) For Extended-Release Oral Suspension at SLEEP 2025GlobeNewswire– 14 abstracts accepted, including four oral presentations – – Interim analysis of real-world REFRESH study demonstrated clinically significant efficacy and improvement of EDS for patients who switched from
- 1y agoAVDLAvadel Pharmaceuticals to Present at the Jefferies Global Healthcare ConferenceGlobeNewswireDUBLIN, Ireland, May 29, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management
- 1y agoAVDLAvadel Pharmaceuticals Expands Leadership Team with Appointment of Susan Rodriguez as Chief Operating OfficerGlobeNewswireDUBLIN, May 13, 2025 (GLOBE NEWSWIRE) -- DUBLIN, May 13, 2025 – Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced the
- 1y agoAVDLAvadel Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual BioConnect Investor ConferenceGlobeNewswireDUBLIN, May 13, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will
- 1y agoAVDLAvadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireDUBLIN, May 08, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel's Board of
- 1y agoAVDLAvadel Pharmaceuticals Reports First Quarter 2025 Financial Results and Raises GuidanceGlobeNewswire-- Generated $52.5 million in net revenue from sales of LUMRYZ™, a 93% increase over the first quarter of 2024 -- -- 2,800 patients on LUMRYZ as of March 31, 2025, a net increase of 300 patients since December
- 1y agoAVDLAvadel Pharmaceuticals Announces Favorable Ruling in Appeal of Delaware Court InjunctionGlobeNewswire- With this ruling, Avadel can seek and be granted FDA approval for LUMRYZ in Idiopathic Hypersomnia - - Federal Circuit decision permits new clinical trials and further development of LUMRYZ™ for the treatment
- 1y agoAVDLAvadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2025 Financial Results on May 7GlobeNewswireDUBLIN, Ireland, April 30, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a
- 1y agoAVDLAvadel and nference Announce Publication of Real-World Data on Sodium Oxybate Treatment Patterns in the Journal of Clinical NeuroscienceGlobeNewswire-- Retrospective analysis reveals no significant differences in comorbidities in narcolepsy patients treated vs. not treated with sodium oxybate -- -- One third of patients taking immediate-release, twice-nightly sodium
- 1y agoAVDLAvadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireDUBLIN, April 10, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel's Board of
- 1y agoAVDLAvadel Pharmaceuticals Provides Update at Needham Virtual Healthcare ConferenceGlobeNewswireDUBLIN, April 08, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today presented at the 24th Annual Needham Virtual
- 1y agoAVDLAvadel Pharmaceuticals to Present at the 24th Annual Needham Healthcare ConferenceGlobeNewswireDUBLIN, April 01, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will
- 1y agoAVDLAvadel Announces Publications in CNS Drugs Supplement Highlighting Key Clinical Issues for People with Narcolepsy and Their CliniciansGlobeNewswireDUBLIN, March 25, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced the publication of six manuscripts
- 1y agoAVDLAvadel Pharmaceuticals to Present at Upcoming Investor ConferencesGlobeNewswireDUBLIN, Ireland, March 05, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management
- 1y agoAVDLAvadel Pharmaceuticals Reiterates 2025 Guidance as it Reports Fourth Quarter and Full Year 2024 Financial ResultsGlobeNewswire-- LUMRYZ™ generated $50.4 million in sales in the fourth quarter, up 158% year-over-year, taking the full-year total to $169.1 million, in line with preliminary results published January 8 -- Reiterates 2025
- 1y agoAVDLAvadel Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on March 3GlobeNewswireDUBLIN, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call
- 1y agoAVDLAvadel Pharmaceuticals Appoints Kevin Springman as Vice President of SalesGlobeNewswireDUBLIN, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced that Kevin Springman has joined the
- 1y agoAVDLAvadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireDUBLIN, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel's Board of